Description

Simple

A medication used to treat patients with inhalational anthrax or to prevent disease in patients who have been exposed to anthrax.

Clinical

A monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate.

Overview

Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.

Pharmacology

Indication

Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

Pharmacodynamic

Information currently not available.

Mechanism of action

Raxibacumab is a monoclonal antibody that binds free PA with an affinity equilibrium dissociation constant (Kd) of 2.78 ± 0.9 nM. Raxibacumab inhibits the binding of PA to its cellular receptors, preventing the intracellular entry of the anthrax lethal factor and edema factor, the enzymatic toxin co... Read more

Absorption

Raxibacumab does not cross the blood-brain-barrier. When a single IV dose of 40 mg/kg was administered to healthy, male and female human subjects, the pharmacokinetic parameters are as follows:
Cmax = 1020.3 ± 140.6 mcg/mL;
AUCinf = 15845.8 ± 4333.5 mcg·day/mL.
Bioavailability is also dependent o... Read more

Protein binding

Information currently not available.

Volume of distribution

Steady state volume of distribution exceeded plasma volume. This suggests that there is some distribution into the tissues.

Clearance

Clearance values were much smaller than the glomerular filtration rate indicating that there is virtually no renal clearance of raxibacumab.

Half life

Mean terminal elimination half-lives of raxibacumab are as follows:
IM dose = 15-19 days;
IV dose = 16-19 days

Route of elimination

Information currently not available.

Toxicity

The most frequently reported adverse reactions were rash, pain in extremity, pruritus, and somnolence.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Raxibacumab
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abciximab
The risk or severity of adverse effects can be increased when Abciximab is combined with Raxibacumab.
Abituzumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Abituzumab.
Abrilumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Abrilumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Raxibacumab.
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Raxibacumab.
Aducanumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Aducanumab.
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with Raxibacumab.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Raxibacumab.
Alirocumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Alirocumab.
Amatuximab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Amatuximab.
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with Raxibacumab.
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Anetumab ravtansine.
Anifrolumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Anifrolumab.
Anthrax immune globulin human
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Raxibacumab.
Apolizumab
The risk or severity of adverse effects can be increased when Apolizumab is combined with Raxibacumab.
Apomab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Apomab.
Ascrinvacumab
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Ascrinvacumab.
Asfotase alfa
The risk or severity of adverse effects can be increased when Raxibacumab is combined with Asfotase alfa.
1 References
  1. 1 . Mazumdar S: Raxibacumab. MAbs. 2009 Nov-Dec;1(6):531-8. Epub 2009 Nov 29.PubMed: 20068396